Will Access To HCV Meds Improve After Harvoni Approval?
Executive Summary
Participants at AASLD/EASL special meeting on HCV complain that payers have limited coverage to only the sickest patients. The approval of Harvoni, which despite criticisms of its pricing will be much cheaper than Sovaldi/Olysio combination therapy, is expected to ease access for broader coverage.